New treatment options for advanced pancreatic cancer (Q37345841)

19 August 2017

1 reference

title

New treatment options for advanced pancreatic cancer (English)

1 reference

19 August 2017

1 reference

Eithne Costello

3

0 references

John P Neoptolemos

object named as

John P Neoptolemos

series ordinal

5

0 references

William Greenhalf

series ordinal

4

object named as

William Greenhalf

1 reference

19 August 2017

1

Gary Middleton

1 reference

19 August 2017

2

Paula Ghaneh

1 reference

19 August 2017

1 October 2008

1 reference

Expert Review of Gastroenterology & Hepatology

19 August 2017

1 reference

19 August 2017

2

1 reference

19 August 2017

5

1 reference

19 August 2017

673-696

1 reference

Cancer burden in the year 2000. The global picture

19 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

21 January 2018

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

A new approach to managing intraductal papillary mucinous pancreatic neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the anti-epidermal growth factor antibody IMC-C225.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Mechanism of biological synergy between cellular Src and epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

STAT5b, a Mediator of Synergism between c-Src and the Epidermal Growth Factor Receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Identification of Src-specific phosphorylation site on focal adhesion kinase: dissection of the role of Src SH2 and catalytic functions and their consequences for tumor cell behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

c-Src regulates constitutive and EGF-mediated VEGF expression in pancreatic tumor cells through activation of phosphatidyl inositol-3 kinase and p38 MAPK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Ras, PI(3)K and mTOR signalling controls tumour cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Nuclear factor-kappaB in cancer development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Nuclear factor-kB, an unappreciated tumor suppressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Phase II trial of curcumin in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

VEGF-targeted therapy: mechanisms of anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Targeting PDGF signaling in carcinoma-associated fibroblasts controls cervical cancer in mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Effect of Flt3 ligand gene transfer in experimental pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Effects of STI571 (gleevec) on pancreatic cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Discovery of a novel Raf kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, beta-lapachone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Vitamin D signalling pathways in cancer: potential for anticancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Modulation of transcription by PARP-1: consequences in carcinogenesis and inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Potentiation of chemotherapeutics by the Hsp90 antagonist geldanamycin requires a steady serum condition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces or

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Molecular identification of a danger signal that alerts the immune system to dying cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Select forms of tumor cell apoptosis induce dendritic cell maturation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Role of erlotinib in the management of pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Capecitabine in carcinoma of the pancreas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

A "catastrophic hypothesis" for pancreas cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.5.673

21 January 2018

Identifiers

DOI

10.1586/17474124.2.5.673

1 reference

19 August 2017

1 reference

PubMed ID

19072345